Exact Mass: 493.2649
Exact Mass Matches: 493.2649
Found 179 metabolites which its exact mass value is equals to given mass value 493.2649
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Imatinib
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-[[2-Methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
Imatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2742 INTERNAL_ID 2742; CONFIDENCE standard compound CONFIDENCE standard compound; INTERNAL_ID 8521 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3633
C28H35N3O5_(1R,5R,7S,12R)-12-Hydroxy-4,4,4,4,12,14-hexamethyl-4H,13H-spiro[9,14-diazatetracyclo[5.5.2.0~1,9~.0~3,7~]tetradecane-5,8-[1,4]dioxepino[2,3-g]indole]-9,13(10H)-dione
Ala Phe Arg Thr
Ala Phe Thr Arg
Ala Arg Phe Thr
Ala Arg Thr Phe
Ala Thr Phe Arg
Ala Thr Arg Phe
Phe Ala Arg Thr
Phe Ala Thr Arg
Phe Arg Ala Thr
Phe Arg Thr Ala
Phe Thr Ala Arg
Phe Thr Arg Ala
Gly Arg Val Tyr
Gly Arg Tyr Val
Gly Val Arg Tyr
Gly Val Tyr Arg
Gly Tyr Arg Val
Gly Tyr Val Arg
His Ile Pro Gln
His Ile Gln Pro
His Leu Pro Gln
His Leu Gln Pro
His Pro Ile Gln
His Pro Leu Gln
His Pro Gln Ile
His Pro Gln Leu
His Gln Ile Pro
His Gln Leu Pro
His Gln Pro Ile
His Gln Pro Leu
Ile His Pro Gln
Ile His Gln Pro
Ile Pro His Gln
Ile Pro Gln His
Ile Gln His Pro
Ile Gln Pro His
Leu His Pro Gln
Leu His Gln Pro
Leu Pro His Gln
Leu Pro Gln His
Leu Gln His Pro
Leu Gln Pro His
Pro His Ile Gln
Pro His Leu Gln
Pro His Gln Ile
Pro His Gln Leu
Pro Ile His Gln
Pro Ile Gln His
Pro Leu His Gln
Pro Leu Gln His
Pro Gln His Ile
Pro Gln His Leu
Pro Gln Ile His
Pro Gln Leu His
Gln His Ile Pro
Gln His Leu Pro
Gln His Pro Ile
Gln His Pro Leu
Gln Ile His Pro
Gln Ile Pro His
Gln Leu His Pro
Gln Leu Pro His
Gln Pro His Ile
Gln Pro His Leu
Gln Pro Ile His
Gln Pro Leu His
Arg Ala Phe Thr
Arg Ala Thr Phe
Arg Phe Ala Thr
Arg Phe Thr Ala
Arg Gly Val Tyr
Arg Gly Tyr Val
Arg Thr Ala Phe
Arg Thr Phe Ala
Arg Val Gly Tyr
Arg Val Tyr Gly
Arg Tyr Gly Val
Arg Tyr Val Gly
Thr Ala Phe Arg
Thr Ala Arg Phe
Thr Phe Ala Arg
Thr Phe Arg Ala
Thr Arg Ala Phe
Thr Arg Phe Ala
Val Gly Arg Tyr
Val Gly Tyr Arg
Val Arg Gly Tyr
Val Arg Tyr Gly
Val Tyr Gly Arg
Val Tyr Arg Gly
Tyr Gly Arg Val
Tyr Gly Val Arg
Tyr Arg Gly Val
Tyr Arg Val Gly
Tyr Val Gly Arg
Tyr Val Arg Gly
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(1R,9S,10S,11S)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-8-[2-(3-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(5R,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5R,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
methyl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
methyl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
1-[[(4R,5R)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
N-[(5R,6R,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6S,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
methyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
(1S,9R,10R,11R)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
methyl N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(1S,6R,7R,8R)-6-Hydroxy-4,4,6,10,10,13-hexamethylspiro[10H-[1,4]dioxepino[2,3-g]indole-8,11-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-9,14-dione
(1'r,3'r,7's,8r,12'r)-9,12'-dihydroxy-4,4,4',4',12',14'-hexamethyl-9',14'-diazaspiro[[1,4]dioxepino[2,3-g]indole-8,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-one
14-ethyl-2,6-dihydroxy-4,19-dimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-21-yl acetate
3beta-acetoxynorerythrosuamine
{"Ingredient_id": "HBIN008156","Ingredient_name": "3beta-acetoxynorerythrosuamine","Alias": "3\u03b2-acetoxynorerythrosuamine","Ingredient_formula": "C26H39NO8","Ingredient_Smile": "CC1C2C(CCC1=CC(=O)OCCNC)C3(CCC(C(C3C(=O)C2O)(C)C(=O)OC)OC(=O)C)C","Ingredient_weight": "493.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25340;265","TCMSP_id": "NA","TCM_ID_id": "8175;24321","PubChem_id": "101606278","DrugBank_id": "NA"}